Loading...
XASX
RGT
Market cap11mUSD
Apr 29, Last price  
0.42AUD
Name

MGC Pharmaceuticals Ltd

Chart & Performance

D1W1MN
P/E
P/S
5.37
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
62.74%
Revenues
3m
-27.10%
02,627,9461,905,6622,110,860351,663000002,197120,242296,811656,2372,034,6492,962,8974,646,9883,387,567
Net income
-21m
L+20.17%
0-81,771-1,877,328-1,945,590-2,630,6591,935,168-290,880-766,897-5,337,815-3,797,791-6,157,144-8,144,361-8,246,340-1,903,672-20,022,987-13,504,469-17,328,780-20,823,584
CFO
-12m
L-28.76%
0-1,626,583-460,263-416,042-1,042,541-338,824-379,448-536,078-472,738-617,707-3,220,501-4,655,863-5,886,790-6,354,210-10,140,478-12,433,708-16,824,483-11,985,175

Profile

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
IPO date
Dec 21, 2006
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
3,388
-27.10%
Cost of revenue
19,469
Unusual Expense (Income)
NOPBT
(16,081)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(16,081)
Net income
(20,824)
20.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,451
BB yield
-16,633.73%
Debt
Debt current
9,370
Long-term debt
769
Deferred revenue
4,278
Other long-term liabilities
21
Net debt
9,899
Cash flow
Cash from operating activities
(11,985)
CAPEX
(190)
Cash from investing activities
606
Cash from financing activities
9,732
FCF
(13,499)
Balance
Cash
240
Long term investments
Excess cash
70
Stockholders' equity
(8,032)
Invested Capital
14,054
ROIC
ROCE
EV
Common stock shares outstanding
2,947
Price
0.01
-68.75%
Market cap
15
-99.96%
EV
9,285
EBITDA
(15,329)
EV/EBITDA
Interest
257
Interest/NOPBT